ProShares Trust - ProShares UltraShort S&P500 -2x Shares
SDS
Get informed when a big investor buys or sells
+ FollowMarket Cap$39.35B
Close$
$-69.84
230.5% downside
Current Fair Value
230.5% downsideOvervalued by 230.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $39.35 Billion |
|---|---|
| Enterprise Value | $39.17 Billion |
| Dividend Yield | $3.03 (5.30%) |
| Earnings per Share | $-4.09 |
| Beta | -1.87 |
| Outstanding Shares | 3,934,738 |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | -58.3 |
|---|---|
| PEG | -10.21 |
| Price to Sales | 17.84 |
| Price to Book Ratio | 0.78 |
| Enterprise Value to Revenue | 2999.97 |
| Enterprise Value to EBIT | -521.18 |
| Enterprise Value to Net Income | -556 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.1659▼ 96.07% |
|---|---|
| Total Calls | 366,400▲ 10.94% |
| Total Puts | 427,200▼ 39.18% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 42.65%▲ 26.45% |
|---|---|
| Total Invested | $126.29M▲ 189.23% |
| Investors Holding | 61▲ 9.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...